Catalyst Pharmaceuticals settles patent litigation with Teva, delaying generic Firdapse launch until 2035. Legal actions against other defendants remain ongoing.
which is facing a case focused on Catalyst’s Firdapse patent that expires in 2037. In the Notice Letter in January 2023, Teva stated that it intended to market a generic version of Firdapse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback